PRODUCT DESCRIPTION:

Entecavir Tablets are potent oral antiviral agents used for the treatment of chronic Hepatitis B virus (HBV) infection in adults and children above 2 years with active viral replication and evidence of liver inflammation.

As a guanosine nucleoside analogue, Entecavir inhibits HBV polymerase with high selectivity and potency, helping to reduce viral load and improve liver function over time.

Available in strengths of 0.5 MG and 1 MG, Entecavir is an integral part of national hepatitis programs and long-term viral suppression protocols.

Produced under stringent GMP-compliant facilities, this product ensures therapeutic consistency, ideal for public health tenders and ethical procurement.

Formulation & Presentation:

• Dosage Form: Tablets
• Presentation: Available in Blister Pack or HDPE Bottle (As per market requirement)
• Available Strengths:
  • Entecavir Tablets: 0.5 MG
  • Entecavir Tablets: 1 MG
• Route of Administration: Oral (As per physician’s discretion or therapeutic indication)

Therapeutic Indications:

• Chronic Hepatitis B infection in nucleoside-treatment-naive adults with evidence of active viral replication
• Hepatitis B treatment in patients with compensated or decompensated liver disease
• Pediatric use in HBV-positive children aged ≥2 years with liver inflammation

Side Effects:

• COMMON:
  • Headache
  • Fatigue
  • Dizziness
  • Nausea
  • Diarrhea
• SERIOUS (RARE):
  • Lactic acidosis
  • Hepatomegaly with steatosis
  • Exacerbation of hepatitis upon discontinuation
  • Renal dysfunction in long-term therapy
• PRECAUTIONS:
  • Monitor renal function during long-term therapy
  • Regular liver function tests are recommended
  • Not recommended during pregnancy unless clearly needed
  • Discontinuation may cause rebound hepatitis flare—monitor closely
  • Dose adjustment required in renal impairment